羅氏NimbleGen將推出多樣本混合捕獲實驗方案以及全基因組外顯子液相捕獲三代產(chǎn)品
二代測序技術正在不斷突破高通量以及低測序成本的極限。定向測序更是當前最有效控制測序成本同時獲得關鍵序列信息的首選。NimbleGen即將推出序列捕獲前的多樣本混合實驗方案,希望以此更好地優(yōu)化序列捕獲技術以配合二代測序平臺的高通量,進而減少實驗時間并降低測序費用。這一新技術利用不同條形碼序列來結合不同樣本,然后混合一次實驗中進外顯子或定制目標區(qū)域的液相捕獲。
羅氏NimbleGen的首席執(zhí)行官Frank Pitzer說:“我們很高興向所有研究人員突出這個高效而且低成本的實驗方案。相信通過這一方法,研究人員可以提高研究項目的樣本通量,以此增強研究項目在統(tǒng)計學上的重要性!
多樣本混合實驗方案的同時,新一代的外顯子液相捕獲產(chǎn)品也會同時推出。這一新產(chǎn)品將可捕獲64M的基因組序列,包括所有外顯子以及miRNA,它含與其他NimbleGen液相捕獲產(chǎn)品相同的2.1M高密度探針,以確保高效、均一、特異、全面的定向捕獲,將成為市場覆蓋面最廣的序列捕獲產(chǎn)品之一。
Pitzer先生介紹說:“這個新的產(chǎn)品, NimbleGen SeqCap EX Exome Library v3.0延續(xù)了NimbleGen一貫以來產(chǎn)品的高效和均一的特點,這一點得到了行業(yè)內(nèi)的認可,許多文獻中的實驗結果也可以證明。例如在最近Nature Biotechonlogy雜志中刊登的一篇文章1,對于三種外顯子組捕獲產(chǎn)品的捕獲序列進行測序后比較,在同樣獲得80M測序數(shù)據(jù)的情況下,NimbleGen有97%的目標序列達到10x以上 的測序深度,而其他產(chǎn)品只有90%。此外,NimbleGen SeqCap EX Exome Library v3.0產(chǎn)品將覆蓋更廣泛的區(qū)域,包括RefSeq, CCDS Vega以及Ensemble Database中的外顯子相關區(qū)域!
于此同時,研究人員仍然可以選擇NimbleGen SeqCap EX Exome Library v2.0產(chǎn)品,它仍將是針對RefSeq數(shù)據(jù)庫的外顯子序列最為經(jīng)濟有效的測序捕獲工具。而兩項新產(chǎn)品的相關數(shù)據(jù)信息,將在最近在加拿大蒙特利爾舉辦的美國人類基因學年會中發(fā)布,敬請留意后續(xù)報道。
更多有關羅氏NimbleGen產(chǎn)品,請訪問www.nimblegen.com.
文中所涉及的文獻
(1) Clark et al., Performance comparison of exome DNA sequencing technologies (2011)
Nature Biotechnology Published online 25 September 2011 doi:1038/nbt.1975
Roche NimbleGen Announces New Pre-capture Multiplexing for Target Enrichment Technology in Sequencing
With the decreasing cost and increasing throughput of sequencing, researchers require a high-performance, cost-effective sample preparation pipeline for targeted sequencing. To enable researchers to more readily match targeted sequencing sample preparation throughput to the ever increasing throughput of next-generation sequencing, Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) announces the imminent launch of a pre-capture multiplex target enrichment protocol. This new pre-capture multiplex protocol enables multiple DNA samples to be barcoded and captured in a single SeqCap EZ Library reaction for exome or custom capture experiments.
“We are extremely excited to provide researchers with a high performance, cost-effective pre-capture multiplex protocol that should allow researchers to increase the size of their studies, and thus, the statistical relevance,” stated Frank Pitzer, CEO of Roche NimbleGen.
The pre-capture multiplex protocolwill be launched for an additional, more comprehensive Exome capture product. This new product will employ the same high-density probe technology that ensures high capture efficiency in all of its existing SeqCap EZ products. However, the new Exome product will target 64Mb of coding exons and miRNAs, providing researchers with an efficient target enrichment product with the most comprehensive coverage of coding regions.
“The new extension of our target enrichment portfolio, NimbleGen SeqCap EZ Exome Library v3.0, will provide researchers with the same industry-renown performance and uniformity that researchers worldwide have proven in numerous recent publications. In one recent study in Nature Biotechnology1, with 80M reads, ~97% of the target bases are covered by more than 10-fold using NimbleGen SeqCap EZ where only ~90% of the target bases are covered by competitive technologies. Additionally, SeqCap EZ Exome Library v3.0 will target the most comprehensive collection of exons in the market as defined by the RefSeq, CCDS, Vega, and Ensembl databases,” Pitzer noted. Roche NimbleGen will continue to offer the high-performance SeqCap EZ Exome v2.0 product, as an efficient tool for researchers who want to generate extremely cost-effective sequencing data for RefSeq exons.
Roche plans to release further information of both the pre-capture multiplexing protocol and the NimbleGen SeqCap EZ Exome v3.0 at the American Society of Human Genetics (ASHG) annual meeting (for more information visit Roche at ASHG booth number 502) next week in Montreal, Canada.
For more information about Roche NimbleGen, please visit www.nimblegen.com
(1) Clark et al., Performance comparison of exome DNA sequencing technologies (2011)
Nature Biotechnology Published online 25 September 2011 doi:1038/nbt.1975